top of page
VERESCA PRECISION ONCOLOGY 3NDx OTI.png

Investigator - Initiated Trial Evaluation Program

Enlist the support of Veresca Precision Oncology to improve the clinical efficacy of your MultiRx evaluation through patient enrichment using the Veresca FOXC1 Test.

Screenshot (962).png

Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression. 

​

Presented by:  Partha S. Ray, MD

Oral Mini Session 2 - LBA 1

15:10  | 08 Dec 2022 | Room B

​

Screenshot (963)_edited.jpg

Embargoed Until 10 DEC 22

Screenshot (772).png

ESMO Oral Presentation LBA2

Frankfurt Hall

5 May 2022 10:45 am (CEST)

Onconostic Technologies, Inc.

 Partha S. Ray, MD

​

​

Assessment  of Ki67 and FOXC1-based response predictor tracking proliferation and plasticity as a complementary diagnostic for neoadjuvant Olaparib + Paclitaxel + Darvlumab in primary TNBC: retrospective analysis of the I-SPY Trial

VID220519 VIDEO COVER.png
Screenshot (957).png

EMUC Presentation

Poster EPO 29

Screenshot (960)_edited.jpg
Screenshot (777).png

ASCO Presentation 

Abstract 569 - Poster 341 

title.png
labortorio e oncologia.png
gregorio maranon.png
VERESCA PRECISION ONCOLOGY 3NDx OTI.png
ESMO 2022 PRSENTATION
VERESCA BLUE WORDMARK_edited.png

VERESCA products are covered by one or more patents or pending patent applications worldwide.  See www.foxc1.info/patents 

           and VERESCA are trademarks owned by or licensed to the affiliated companies of 3N Diagnostics Ltd. and Onconostic Technologies, Inc.  ®  VERESCA is a registered trademark in the European Union and certain other countries throughout the world.  © 2020 The VERESCA Affiiates

3N Diagnostics Ltd.  Murray House, 1 Murray Street, Belfast Antrim BT1 6DN Northern Ireland, UK

bottom of page